(NASDAQ: BNTC) Benitec Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 75.03%.
Benitec Biopharma's earnings in 2026 is -$46,303,000.On average, 8 Wall Street analysts forecast BNTC's earnings for 2026 to be -$40,716,757, with the lowest BNTC earnings forecast at -$50,164,199, and the highest BNTC earnings forecast at -$38,236,374. On average, 7 Wall Street analysts forecast BNTC's earnings for 2027 to be -$37,635,173, with the lowest BNTC earnings forecast at -$53,530,923, and the highest BNTC earnings forecast at $2,885,764.
In 2028, BNTC is forecast to generate -$33,406,154 in earnings, with the lowest earnings forecast at -$43,430,749 and the highest earnings forecast at -$16,593,143.